Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials

INTRODUCTION: Baricitinib is an oral selective Janus kinase (JAK)1/JAK2 inhibitor approved in Japan and the European Union for the treatment of atopic dermatitis (AD). The aim of this study is to report pooled safety data for baricitinib in the Japanese subpopulation of the clinical development prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Katoh, Norito, Takita, Yasushi, Isaka, Yoshitaka, Nishikawa, Atsushi, Torisu-Itakura, Hitoe, Saeki, Hidehisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579605/
https://www.ncbi.nlm.nih.gov/pubmed/36255569
http://dx.doi.org/10.1007/s13555-022-00828-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579605/
https://www.ncbi.nlm.nih.gov/pubmed/36255569
http://dx.doi.org/10.1007/s13555-022-00828-5

Ejemplares similares